Higher REV7/MAD2L2 expression was associated with higher survival probabilities in pancreatic cancer, ovarian cancer and breast cancer, while low levels of REV7/MAD2L2 exhibited an unfavourable outcome [40]. Here, MAD2L2 is linked to breast cancer.